• cfDNA in Ocular Histiocytosis
    Nov 7 2024

    Dr. Rajesh Rao speaks with Dr. Jasmine H. Francis on whether sequencing of plasma-derived ctDNA can noninvasively diagnose ocular-involving histiocytosis. From her Ophthalmology Science article, “Plasma-Derived Cell-Free DNA for the Diagnosis of Ocular-Involving Histiocytosis.”

    Plasma-Derived Cell-Free DNA for the Diagnosis of Ocular-Involving Histiocytosis. Francis, Jasmine H. et al. Ophthalmology Science, Volume 4, Issue 5.

    Show more Show less
    28 mins
  • AI for Pediatric Pseudopapilledema and True Papilledema
    Oct 24 2024

    Can artificial intelligence distinguish between pseudopapilledema and true papilledema in children? Dr. Drew Carey interviews author Dr. Melinda Y. Chang on whether AI can be used to improve the diagnostic process in children with abnormal optic nerves and concern for elevated intracranial pressure. From her Ophthalmology Science article, “Artificial Intelligence to Differentiate Pediatric Pseudopapilledema and True Papilledema on Fundus Photographs”

    Artificial Intelligence to Differentiate Pediatric Pseudopapilledema and True Papilledema on Fundus Photographs. Chang, Melinda Y. et al. Ophthalmology Science, Volume 4, Issue 4.

    Show more Show less
    15 mins
  • Evaluating Primary Treatment for People with Advanced Glaucoma
    Oct 10 2024

    Does primary trabeculectomy or medical treatment produce better outcomes in terms of quality of life, clinical effectiveness, and safety in patients with advanced glaucoma? Dr. Drew Carey interviews Dr. Anthony J. King on the results of his recent study asking this question published in Ophthalmology, “Evaluating Primary Treatment for People with Advanced Glaucoma: Five-Year Results of the Treatment of Advanced Glaucoma Study.”

    Evaluating Primary Treatment for People with Advanced Glaucoma. King, Anthony J. King, Anthony et al. Ophthalmology, Volume 131, Issue 7, 759 – 770.

    Join Ophthalmology’s Editor-in-Chief, Russell Van Gelder, as he presents “The Year in Literature: Editor’s Choice Highlights From the Ophthalmology Journal Family” in Chicago at AAO 2024 on Sunday October 20, 2024, at 2pm local time in McCormick Place South Building Room S406A. Search “SYM48” in the Mobile Meeting Guide for more information.

    Show more Show less
    25 mins
  • Ophthalmology Education in Medical Schools
    Sep 26 2024

    How has ophthalmology medical education changed over time in medical school curriculums? Dr. Edmund Tsui speaks with Drs. Ashish Agar and Sascha Spencer on their review of global trends in medical school ophthalmology education from their Ophthalmology article, “A Systematic Review of Ophthalmology Education in Medical Schools: The Global Decline.”

    A Systematic Review of Ophthalmology Education in Medical Schools. Spencer, Sascha K.R. et al. Ophthalmology, Volume 131, Issue 7, 855 – 863.

    Join Ophthalmology’s Editor-in-Chief, Russell Van Gelder, as he presents “The Year in Literature: Editor’s Choice Highlights From the Ophthalmology Journal Family” in Chicago at AAO 2024 on Sunday October 20, 2024, at 2pm local time in McCormick Place South Building Room S406A. Search “SYM48” in the Mobile Meeting Guide for more information.

    Show more Show less
    28 mins
  • Adverse Events with Opioids and Ophthalmic Surgery
    Sep 12 2024

    Ophthalmologists are not spared from the opioid epidemic. Recent studies have shown that opioids continue to be prescribed after ophthalmic surgeries. Dr. Drew Carey interviews Dr. Matthew R. Starr on his retrospective study published in Ophthalmology, “Hospitalization, Overdose, and Mortality After Opioid Prescriptions Tied to Ophthalmic Surgery.”

    Hospitalization, Overdose, and Mortality After Opioid Prescriptions Tied to Ophthalmic Surgery. Thao, Viengneesee et al. Ophthalmology, Volume 131, Issue 8, 943 – 949.

    Join Ophthalmology’s Editor-in-Chief, Russell Van Gelder, as he presents “The Year in Literature: Editor’s Choice Highlights From the Ophthalmology Journal Family” in Chicago at AAO 2024 on Sunday October 20, 2024, at 2pm local time in McCormick Place South Building Room S406A. Search “SYM48” in the Mobile Meeting Guide for more information.

    Show more Show less
    29 mins
  • CRISPR Assay for Fungal Keratitis
    Aug 29 2024

    The RID-MyC assay, a CRISPR/Cas12a-based test, offers swift and reliable detection of Fungal Keratitis, enhancing diagnostic capabilities at point-of-care settings. Dr. Rajesh Rao interviews Dr. Siddharth Narendran on the development of this assay from his Ophthalmology Science article, “Development and Clinical Evaluation of a CRISPR/Cas12a-Based Nucleic Acid Detection Platform for the Diagnosis of Keratomycoses.”

    Development and Clinical Evaluation of a CRISPR/Cas12a-Based Nucleic Acid Detection Platform for the Diagnosis of Keratomycoses. Deivarajan, Hanith Raj et al. Ophthalmology Science, Volume 4, Issue 5.

    Join Ophthalmology’s Editor-in-Chief, Russell Van Gelder, as he presents “The Year in Literature: Editor’s Choice Highlights From the Ophthalmology Journal Family” in Chicago at AAO 2024 on Sunday October 20, 2024, at 2pm local time in McCormick Place South Building Room S406A. Search “SYM48” in the Mobile Meeting Guide for more information.

    Show more Show less
    24 mins
  • Bevacizumab in High-Risk Penetrating Keratoplasty
    Aug 15 2024

    Dr. Matt Feng is joined by Dr. Thomas H. Dohlman to discuss the effectiveness of topical and subconjunctival bevacizumab in suppressing vascularization in graft and host bed after high-risk corneal transplantation, from his Ophthalmology Science article “Suppression of Neovascularization by Topical and Subconjunctival Bevacizumab After High-Risk Corneal Transplantation”

    Suppression of Neovascularization by Topical and Subconjunctival Bevacizumab After High-Risk Corneal Transplantation. Dohlman, Thomas H. et al. Ophthalmology Science, Volume 4, Issue 4.

    Show more Show less
    23 mins
  • Hearing Dysfunction with Teprotumumab
    Aug 1 2024

    What does hearing dysfunction have to do with an ophthalmology podcast? Listen up and find out as Dr. Drew Carey interviews Dr. Jamie A. Keen and Dr. Erin M. Shriver on the risks of using teprotumumab to hearing function in treatment of thyroid eye disease. From their article “Frequency and Patterns of Hearing Dysfunction in Patients Treated with Teprotumumab.”

    Frequency and Patterns of Hearing Dysfunction in Patients Treated with Teprotumumab. Keen, Jamie A. et al. Ophthalmology, Volume 131, Issue 1, 30 – 36.

    Show more Show less
    25 mins